Differentiating the signal transduction pathways governing development and prognosis of breast cancer subtypes is vital to design optimal intervention strategies especially for the ER(−) subtype that has fewer treatment options than the ER(+) subtype [5]. The gene discussed is ESR1; the disease is breast cancer.